Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Patients with Melanoma
Neurol 101:e2472-e2482, Pepys,J.,et al, 2023
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016
JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Brain Metastases
The Neurologist 10:31-46, Klos,K.J.&O'Neill,B.P., 2004
Treatment of Brain Metastases of Malignant Melanoma with Temozolomide
NEJM 345:621-622, Biasco,G.,et al, 2001
The Role of Radiation Therapy Following Resection of Single Brain Metastasis from Melanoma
Neurol 40:158-160, Hagen,N.A.,et al, 1990
Meningeal Carcinomatosis
Arch Neurol 38:696-699, Theodore,W.H.,et al, 1981
Malignant Melanoma and Central Nervous System Metastases, Incidence, Diagnosis, Treatment and Survival
Cancer 42:660-668, Amer,M.H.,et al, 1978
Infiltration of the Leptomeninges by Systemic Cancer:a Clinical & Pathologic Study
Arch Neurol 30:122, Olson,M.E.,et al, 1974